We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
201
Rocket Pharmaceuticals
RCKT
$336M
– –
-53,163
Closed -$404K
SAGE
202
PUT
DELISTED
Sage Therapeutics
SAGE
– –
-206
Closed -$1.64M
SLNO
203
DELISTED
Soleno Therapeutics
SLNO
– –
-3,308
Closed -$127K
TGTX icon
204
CALL
TG Therapeutics
TGTX
$8.3B
– –
-490
Closed -$492K
TOVX icon
205
Theriva Biologics
TOVX
$9.63M
– –
-19
Closed -$95K
UTHR icon
206
United Therapeutics
UTHR
$26B
– –
-53,116
Closed -$6.78M
UTHR icon
207
PUT
United Therapeutics
UTHR
$26B
– –
-1,016
Closed -$13.2M
VKTX icon
208
Viking Therapeutics
VKTX
$3.88B
– –
-486,491
Closed -$525K
VTGN icon
209
VistaGen Therapeutics
VTGN
$9.94M
– –
-851
Closed -$48K
XLV icon
210
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.1B
– –
-719
Closed -$5.7M
XNTK icon
211
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.97B
– –
-442
Closed -$3.41M
GRDX
212
GridAI Technologies Corp
GRDX
$19.1M
– –
0
– -$161K
CSCI
213
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-673
Closed -$67K
VIRX
214
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-56
Closed -$525K
LUMO
215
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-15,339
Closed -$1.18M
ASXC
216
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-266,103
Closed -$3.1M
GENE
217
DELISTED
Genetic Technologies Ltd.
GENE
– –
-2,681
Closed -$48K
BPTH
218
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-298
Closed -$462K
MRTX
219
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-255,100
Closed -$921K
CYTO
220
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-2
Closed -$103K
SRNE
221
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-17,300
Closed -$35K
OTIC
222
DELISTED
Otonomy, Inc.
OTIC
– –
-50,205
Closed -$677K
OTIC
223
PUT
DELISTED
Otonomy, Inc.
OTIC
– –
-130
Closed -$245K
CLVS
224
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-7,065
Closed -$560K
GPL
225
DELISTED
Great Panther Mining Limited
GPL
– –
-1,732
Closed -$22K
6 7 8
9
10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.